Procore signs multi-year strategic collaboration agreement with AWS
Investing.com - RAPT Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
RAPT Therapeutics announced earnings per share of $-0.63 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.70 on revenue of $231K.
RAPT Therapeutics 's are down 72% and is trading at $20.58 , still down 49.48% from its 52 week high of $40.74 set on Friday, January 7, 2022.
RAPT Therapeutics shares gained 18.14% to trade at $20.58 in intra-day trade the report.
RAPT Therapeutics follows other major Healthcare sector earnings this month
RAPT Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar